Updates are available Correction dated 2023-03-21
Click to view Correction: https://doi.org/10.1038/s41577-023-00869-7
-
Authors
Scherlinger, Marc https://orcid.org/0000-0002-9453-5895
Richez, Christophe https://orcid.org/0000-0002-3029-8739
Tsokos, George C. https://orcid.org/0000-0001-9589-2360
Boilard, Eric https://orcid.org/0000-0001-6319-6432
Blanco, Patrick
- License Information
-
More Information
Article History
Accepted: 15 December 2022
First Online: 27 January 2023
Change Date: 21 March 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41577-023-00869-7
Competing interests
: C.R. has received consulting or speaker fees from AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Biogen, Eli Lilly, GlaxoSmithKline, Janssen Novartis and Pfizer and grants from Biogen, Eli Lilly and Nordic Pharma, all unrelated to this work. M.S. has received consulting fees from Sandoz, Amgen and Nordic Pharma, all unrelated to this work. The other authors report no competing interests.
